Zevra Q3 net loss $33.2M; FDA approval of MIPLYFFA for NPC marks key milestone

ZEVRA THERAPEUTICS, INC.

2025-Q3 EPS reported -$1.59 vs consensus -$0.04 ▼ miss (-4353.8%)

Net loss of $33.2M ($0.69 per share) vs. $10.4M loss in Q3 2023; revenue $3.7M from French EAP and AZSTARYS royalties.
FDA approved MIPLYFFA (arimoclomol) on Sept. 20 for Niemann-Pick type C; first-ever NPC drug approved.
Cash, equivalents, and investments $95.5M as of Sept. 30; cash runway forecast into 2027, excluding PRV sale.
Completed $64.5M public offering of 10.6M shares at $6.50; closed Iowa/Virginia labs, outsources early R&D.
OLPRUVA revenue minimal; 90 prescription enrollment forms for MIPLYFFA received by Oct. 31, 30% approved for reimbursement.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.